AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.
about
Functional, biophysical, and structural bases for antibacterial activity of tigecyclineEfflux-mediated drug resistance in bacteria: an updateTigecycline: first of a new class of antimicrobial agentsTigecycline: a review of a new glycylcycline antibioticNewer antibacterial drugs for a new century.Tigecycline challenge triggers sRNA production in Salmonella enterica serovar TyphimuriumClinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteriaTigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.In vitro selection of ramR and soxR mutants overexpressing efflux systems by fluoroquinolones as well as cefoxitin in Klebsiella pneumoniaeCurrent and novel antibiotics against resistant Gram-positive bacteriaThe challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosaCase-control study of the risk factors for acquisition of Pseudomonas and Proteus species during tigecycline therapyNew advances in antibiotic development and discovery.Efflux-mediated antimicrobial resistance.Tigecycline: a new glycylcycline for treatment of serious infections.Tigecycline: a novel glycylcycline antibiotic.Multidrug-resistance efflux pumps - not just for resistance.Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York CityAnaerobic choline metabolism in microcompartments promotes growth and swarming of Proteus mirabilisEstablishing the role of tigecycline in an era of antimicrobial resistance.In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for hospital acquired pneumonia.Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance.Tetracycline Antibiotics and Resistance.Analysis of the topology of Vibrio cholerae NorM and identification of amino acid residues involved in norfloxacin resistance.Phenotypic and proteomic characterization of multiply antibiotic-resistant variants of Salmonella enterica serovar Typhimurium selected following exposure to disinfectants.Adaptation of Salmonella enterica Serovar Senftenberg to Linalool and Its Association with Antibiotic Resistance and Environmental Persistence.Induced tigecycline resistance in Streptococcus pneumoniae mutants reveals mutations in ribosomal proteins and rRNA.ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline.Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii.Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocyclineCharacterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae.A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.
P2860
Q24548264-BD3960B2-4BD7-4425-AD36-53D4E93B497AQ24609407-887F4DF0-64D9-4BE0-80D6-6F5A9F1F34A8Q28253736-BA7F72B2-C410-499D-974F-5BEEE8AC3676Q28278979-D0FFF996-9279-4200-83B0-B5FA40F5EDB1Q30433333-338180E7-922F-4791-BA8C-AA5F7A0759F1Q31089832-BC8FEE58-FEF2-4AA4-9E9F-BB19F52F1FD9Q34647294-6952108D-D042-43A2-83CD-8276E7A7EA45Q34803735-536F9C13-AEBB-4FCB-B9E7-65C4C584FB25Q35004824-BAA936B7-B325-45E2-B0C8-171F4553E82CQ35026521-BA9E7276-CF4C-43E5-9E6F-4B5CA1D4F0B6Q35482558-F46F4716-9F34-493D-AF0B-5B66D78553D8Q35637071-5D9F2B21-4643-4C73-9274-064C06ED3799Q35830489-DC9561B4-0DAC-49F7-B906-51DF65C4DFFDQ35960920-7C1AFB7D-3A22-4F9C-B89A-0E7F61F9E869Q36065983-A7927A9B-2315-4F23-AEDE-E212C1D32A9BQ36138147-2A79FFF3-5436-4A5C-9DBD-593551010087Q36218312-61F8A055-C841-48A2-9BBC-CBB41A00B0B6Q36379330-E942B1B8-299F-42BA-99E8-5ED72C53E07FQ36538111-3F2BBBB0-F9F1-4867-95F3-F6ACFC2DC78CQ36757725-4E5FE6ED-3A3B-4300-A49E-D8FD183D5355Q36933389-1993254A-E9EF-47A4-AEA4-EEEAF691A1C5Q37254153-CB3B347E-A99B-4762-B2E2-D61C3B00FBD5Q37261624-0CCE77E8-9307-4F32-A5AD-6B249BA507CAQ37291328-D95DD937-942F-47B1-9342-77D4B1F68B74Q37481794-CF4E2CA3-349A-4E2A-A2CC-42D7582345CCQ38049220-A4F4EF22-243E-46FF-9D8F-15FCE481B461Q38324448-421A8458-B661-4D8A-B4DB-14B4D2582542Q38779243-35A3941A-8060-4DB2-A364-6E8D9A3EDA32Q39076882-57C3CB23-CD4F-418A-9CC0-0F255F0731F6Q40034880-61E8B4A0-5943-4B4D-BA88-7E57D01ABD86Q40309239-472B58EE-F727-4DD9-A187-78E71989B20EQ40727658-7669B44A-8C42-48B7-87B7-29E0590AFF39Q40750517-2E379508-8938-4A70-AE86-CD1746EEA648Q40882661-00D2B056-BF8D-4F77-9E09-1639F25AA405Q41005771-C9E8C87F-6E0A-4873-83C6-4EC0BDCA3F94Q41808583-C1CEFDEF-F6F0-406F-94C9-E682184F3704Q41813766-B30FD617-32C1-4E7E-B48D-8DD43EF8BE8FQ41859877-A7BC9632-0364-42AB-A631-477FFC85DB4EQ42014931-A2BFC4DB-8891-4B4B-9AC9-2BA243DCC0E8Q42028209-181F78F1-CF38-4183-9C55-7E57EA9AE849
P2860
AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
AcrAB multidrug efflux pump is ...... GAR-936) in Proteus mirabilis.
@ast
AcrAB multidrug efflux pump is ...... GAR-936) in Proteus mirabilis.
@en
AcrAB multidrug efflux pump is ...... susceptibility to tigecycline
@nl
type
label
AcrAB multidrug efflux pump is ...... GAR-936) in Proteus mirabilis.
@ast
AcrAB multidrug efflux pump is ...... GAR-936) in Proteus mirabilis.
@en
AcrAB multidrug efflux pump is ...... susceptibility to tigecycline
@nl
prefLabel
AcrAB multidrug efflux pump is ...... GAR-936) in Proteus mirabilis.
@ast
AcrAB multidrug efflux pump is ...... GAR-936) in Proteus mirabilis.
@en
AcrAB multidrug efflux pump is ...... susceptibility to tigecycline
@nl
P2093
P2860
P1476
AcrAB multidrug efflux pump is ...... GAR-936) in Proteus mirabilis.
@en
P2093
Ellen Murphy
Melissa A Visalli
Steven J Projan
P2860
P304
P356
10.1128/AAC.47.2.665-669.2003
P407
P577
2003-02-01T00:00:00Z